

Guru P Sonpavde

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2879158/guru-p-sonpavde-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

541
papers

11,487
citations

48
h-index

92
g-index

602
ext. papers

14,219
ext. citations

4.7
avg, IF

6.3
L-index

#	Paper	IF	Citations
541	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
540	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. <i>European Journal of Cancer</i> , 2022 , 163, 55-65	7.5	0
539	Innovative systemic therapies for penile cancer. <i>Current Opinion in Urology</i> , 2022 , 32, 8-16	2.8	2
538	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.. <i>BJUI Compass</i> , 2022 , 3, 169-172	0.9	1
537	Ongoing Trial and Clinical Trial Endpoint Debate: The Role of Pathologic Response as a Surrogate of Survival Endpoints 2022 , 75-89		
536	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 532-532	2.2	
535	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 569-569	2.2	
534	Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) to predict outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 449-449	2.2	0
533	Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 485-485	2.2	
532	Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 558-558	2.2	
531	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 528-528	2.2	0
530	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS578-TPS578	2.2	
529	Phase 2 trial of CV301 vaccine plus atezolizumab (Atezo) in advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 511-511	2.2	
528	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS588-TPS588	2.2	0
527	Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 565-565	2.2	0
526	Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS591-TPS591	2.2	1
525	A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 518-518	2.2	

524	Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS595-TPS595	2.2	0
523	Association of changes in albumin levels with survival and toxicities in patients (pts) with metastatic urothelial carcinoma (mUC) receiving enfortumab vedotin (EV).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 481-481	2.2	0
522	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 549-549	2.2	
521	Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS585-TPS585	2.2	
520	Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 501-501	2.2	0
519	Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102928	2.2	1
518	Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.. <i>Expert Review of Anticancer Therapy</i> , 2022 ,	3.5	1
517	TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3 β /E-catenin signalling.. <i>Nature Communications</i> , 2022 , 13, 2792	17.4	0
516	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021 , 7, 1339-1346	5.1	20
515	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1125-1135	59.2	110
514	New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2375-2377	12.9	2
513	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2	22
512	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	2
511	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. <i>BJU International</i> , 2021 , 128, 607-614	5.6	2
510	Disparities in reporting and representation of women, older adults and racial minorities in immune checkpoint inhibitor (ICI) clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6549-6549	2.2	
509	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10536-10536	2.2	
508	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4539-4539	2.2	1
507	Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021 , 7, 143-148	1	2

506	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16515 ^{2,2} e16515 ⁰		
505	Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5036-5036	2.2	1
504	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1454-1461	6.1	0
503	Preclinical Models for Bladder Cancer Research. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 613-632	3.1	1
502	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 464-472	6.7	9
501	Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4025-4035	6.9	6
500	Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. <i>Future Oncology</i> , 2021 , 17, 2545-2558	3.6	6
499	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021 , 127, 840-849	6.4	14
498	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
497	Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 299-313	3.5	2
496	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021 , 205, 414-419	2.5	1
495	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021 , 128, 196-205	5.6	3
494	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 443-443	2.2	1
493	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 445-445	2.2	0
492	Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 472-472	2.2	1
491	CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 475-475	2.2	2
490	Association between tumor mutational burden (TMB) and immune-related adverse events (irAEs) in patients (pts) with metastatic urothelial carcinoma (mUC) during checkpoint immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 489-489	2.2	
489	Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 393-393	2.2	5

488	Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD1/L1 inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 414-414	2.2	0
487	Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 453-453	2.2	1
486	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 354-354	2.2	
485	Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 467-467	2.2	1
484	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. <i>Cell Reports</i> , 2021 , 34, 108926	10.6	3
483	Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
482	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021 , 154, 208-214	2.6	1
481	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	2
480	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 425-433	3.3	4
479	Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 733.e1-733.e10	2.8	1
478	Management of Metastatic Penile Cancer 2021 , 125-132		
477	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
476	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2021 ,	6.4	1
475	A global approach to improving penile cancer care.. <i>Nature Reviews Urology</i> , 2021 ,	5.5	4
474	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.. <i>British Journal of Cancer</i> , 2021 ,	8.7	5
473	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. <i>Journal of Medical Economics</i> , 2020 , 23, 967-977	2.4	6
472	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020 , 26, 1041-1043	50.5	72
471	Neoadjuvant therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 603-614	3.5	4

470	Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2305-2317	7.4	5
469	Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival. <i>Radiology</i> , 2020 , 295, 572-580	20.5	3
468	A CD24-p53 axis contributes to African American prostate cancer disparities. <i>Prostate</i> , 2020 , 80, 609-618	4.2	3
467	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 459-464	2.8	26
466	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020 , 39, 4077-4091	9.2	8
465	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors 2020 , 8,		8
464	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020 , 8, 1075-1084	12.5	21
463	Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5018-5018	2.2	8
462	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5095-TPS5095	2.2	4
461	Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 439-439	2.2	50
460	Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 473-473	2.2	1
459	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 507-507	2.2	6
458	Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19390-e19390	2.2	
457	Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5540 ² -5540 ²	2.2	
456	A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) + linrodostat mesylate, followed by adjuvant postsurgical NIVO + linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5091-TPS5091	2.2	0
455	Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17044-e17044	2.2	
454	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5046-5046	2.2	
453	Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17596-e17596	2.2	

452	Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17597-e17597	2.2	0
451	Dissecting outcomes of patients (pts) with . <i>Journal of Clinical Oncology</i> , 2020 , 38, 5043-5043	2.2	
450	Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5048-5048	2.2	
449	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 1155	2.5	
448	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
447	The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing. <i>Cancer Treatment and Research Communications</i> , 2020 , 23, 100165	2	4
446	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020 , 203, 690-698	2.5	38
445	Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. <i>Journal of Urology</i> , 2020 , 203, 1147-1155	2.5	18
444	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020 , 204, 63-70	2.5	11
443	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020 , 204, 1173-1179	2.5	20
442	Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy. <i>European Urology Focus</i> , 2020 , 6, 14-16	5.1	4
441	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020 , 3, 695-699	6.7	19
440	Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e266-e276	3.3	2
439	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. <i>Future Oncology</i> , 2020 , 16, 4359-4368	3.6	31
438	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 555-563	8.7	28
437	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020 , 22, 709-718	8.1	17
436	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 1208-1216	6.4	37
435	PGC1 β suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. <i>Matrix Biology</i> , 2020 , 89, 43-58	11.4	10

434	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>World Journal of Urology</i> , 2020 , 38, 143-150	4	31
433	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. <i>European Urology Oncology</i> , 2020 , 3, 540-543	6.7	6
432	Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. <i>European Urology Oncology</i> , 2020 , 3, 680-686	6.7	7
431	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e651-e659	3.3	4
430	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 821-826	5.9	10
429	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 284-300	7.1	9
428	Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection. <i>American Journal of Roentgenology</i> , 2019 , 1-10	5.4	7
427	Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. <i>Cancer Letters</i> , 2019 , 454, 1-13	9.9	12
426	Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC. <i>Cancer Research</i> , 2019 , 79, 1413-1425	10.1	16
425	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 12	5.4	10
424	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. <i>Molecular Cancer Research</i> , 2019 , 17, 84-96	6.6	26
423	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. <i>Translational Oncology</i> , 2019 , 12, 1416-1424	4.9	7
422	Advanced urothelial cancer: a radiology update. <i>Abdominal Radiology</i> , 2019 , 44, 3858-3873	3	3
421	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4552-4552	2.2	3
420	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 432-432	2.2	1
419	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 435-435	2.2	6
418	Defining platinum-ineligible patients with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 451-451	2.2	9
417	Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 479-479	2.2	3

416	PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 515-515	2.2	1
415	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 653-653	2.2	3
414	EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS497-TPS497	2.2	10
413	Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS504-TPS504	2.2	8
412	Predictive role of CT texture analysis in patients with metastatic urothelial cancer treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 424-424	2.2	
411	Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 476-476	2.2	
410	Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 401-401	2.2	0
409	A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS494-TPS494 ²		
408	Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 226-226	2.2	
407	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 454-454	2.2	
406	Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. <i>Oncology Reviews</i> , 2019 , 13, 455	4.3	6
405	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , 2019 , 25, 2458-2470	12.9	52
404	Systemic treatments for metastatic urothelial carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 201-208	4	8
403	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 1459-1469	6.4	25
402	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019 , 125, 1449-1458	6.4	28
401	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. <i>Cancer</i> , 2019 , 125, 533-540	6.4	26
400	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019 , 125, 1319-1329	6.4	6
399	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019 , 124, 40-46	5.6	7

398	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 95-105	4	12
397	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019 , 75, 88-99	10.2	216
396	Taxane-based Combination Therapies for Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 369-380	5.1	14
395	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018 , 124, 2115-2124	6.4	51
394	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2018 , 45, 143-154	2.9	8
393	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 238.e7-238.e17	2.8	11
392	Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2018 , 121, 871-879	5.6	12
391	Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 2	5.4	5
390	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e277-e287	3.3	4
389	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018 , 73, 751-759	10.2	67
388	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 163-170	5.9	4
387	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e961-e967	3.3	12
386	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , 2018 , 4, 733-736	5.1	16
385	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
384	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018 , 4, 937-945	5.1	6
383	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018 , 16, 1125-1137	6.6	31
382	Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. <i>Bladder Cancer</i> , 2018 , 4, 227-238	1	33
381	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17

380	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. <i>Neoplasia</i> , 2018 , 20, 894-904	6.4	25
379	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 419-430	6.2	1
378	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018 , 36, 1767-1774	4	9
377	A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4588-TPS4588	2.2	5
376	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA5009-LBA5009	2.2	13
375	Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 225-225	2.2	2
374	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 413-413	2.2	9
373	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 451-451	2.2	1
372	A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS538-TPS538	2.2	1
371	A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS539-TPS539	2.2	11
370	Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 190-190	2.2	
369	C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 436-436	2.2	
368	Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 314-314	2.2	
367	Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17041-e17041	2.2	
366	JAVELIN: avelumab another spear to fight urothelial carcinoma. <i>Lancet Oncology, The</i> , 2018 , 19, 5-7	21.7	2
365	Promising immunotherapy for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 109-120	5.4	3
364	Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3189-3191	2.2	8
363	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800328	2.2	49

362	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1
361	Sequential Response to Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With Fusion-Positive Metastatic Urothelial Carcinoma. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	
360	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. <i>Asian Journal of Andrology</i> , 2018 , 20, 230-237	2.8	8
359	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018 , 200, 1207-1214	2.5	10
358	Immunotherapy for advanced penile cancer - rationale and potential. <i>Nature Reviews Urology</i> , 2018 , 15, 721-723	5.5	9
357	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018 , 118, 1434-1441	8.7	17
356	Role of Checkpoint Inhibition in Localized Bladder Cancer. <i>European Urology Oncology</i> , 2018 , 1, 190-198	6.7	17
355	Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 53-59	3.3	1
354	Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. <i>FASEB Journal</i> , 2017 , 31, 1608-1619	0.9	11
353	Drug development in prostate cancer: time to embrace RECIST?. <i>Lancet Oncology, The</i> , 2017 , 18, 419-421	1.7	5
352	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017 , 5, 312-318	12.5	259
351	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 509-512.e9	3.3	1
350	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 557-564	10.2	81
349	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
348	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 635-641	3.3	3
347	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 534-539	3.3	3
346	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1345-1357	7.4	16
345	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e3-24	3.3	3

344	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017 , 71, 281-289	10.2	41
343	Update of systemic immunotherapy for advanced urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 678-686	2.8	10
342	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1240-1267	7.3	172
341	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma 2017 , 5, 68		48
340	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
339	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3181-3188	2.2	53
338	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 804-834	7.3	320
337	The biology of prostate cancer metastases: does oligo differ from polymetastatic?. <i>Current Opinion in Urology</i> , 2017 , 27, 542-546	2.8	5
336	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 347-355	3.7	
335	Editorial Comment. <i>Urology</i> , 2017 , 108, 140-141	1.6	
334	Editorial comment. <i>Urology</i> , 2017 , 106, 124	1.6	
333	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. <i>BJU International</i> , 2017 , 119, 579-584	5.6	12
332	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 213-220.e5	3.3	19
331	CD24 is a genetic modifier for risk and progression of prostate cancer. <i>Molecular Carcinogenesis</i> , 2017 , 56, 641-650	5	12
330	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 23-30.e2	3.3	36
329	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1514-1514	2.2	2
328	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4534-4534	2.2	2
327	Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4582-4582	2.2	0

326	Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 149-149	2.2	8
325	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 346-346	2.2	1
324	Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. <i>Oncotarget</i> , 2017 , 8, 21710-21718	3.3	11
323	Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 29220-29232	3.3	8
322	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16503-e16503	2.2	
321	Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5022-5022	2.2	
320	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16012-e16012	2.2	
319	Impact of perioperative chemotherapy and radiation for locally advanced penile squamous cell carcinoma (PSCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4589-4589	2.2	
318	Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? <i>Eur Urol</i> 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 644-645	10.2	
317	Reply to L.J. Eapen et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3228-9	2.2	
316	Emerging Systemic Therapies for the Management of Penile Cancer. <i>Urologic Clinics of North America</i> , 2016 , 43, 481-491	2.9	9
315	Circulating Biomarkers in Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 369-379	1	24
314	Immunotherapy for Renal Cancer: Sequencing and Combinations. <i>European Urology Focus</i> , 2016 , 2, 582-588	3.8	4
313	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016 , 10, 57-66	1.8	25
312	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. <i>British Journal of Cancer</i> , 2016 , 115, 12-9	8.7	7
311	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016 , 196, 95-100	2.5	41
310	Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 780-5	2.2	6
309	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 4.e11-7	2.8	9

308	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 122-36	7	17
307	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
306	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016 , 69, 624-633	10.2	15
305	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 277-82	2.5	40
304	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. <i>European Urology</i> , 2016 , 69, 980-3	10.2	11
303	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4524-4524	2.2	3
302	Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4528-4528	2.2	4
301	Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4532-4532	2.2	4
300	Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4540-4540	2.2	2
299	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5007-5007	2.2	3
298	Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5035-5035	2.2	0
297	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4576-TPS4576	2.2	8
296	Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 191-191	2.2	1
295	The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 215-215	2.2	1
294	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 357-357	2.2	20
293	Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 358-358	2.2	4
292	Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 385-385	2.2	1
291	Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 451-451	2.2	3

290	Whole-exome sequencing (WES) of penile squamous cell carcinoma (PSCC) to identify multiple recurrent mutations.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 484-484	2.2	1
289	Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. <i>PLoS ONE</i> , 2016 , 11, e0160924	3.7	14
288	Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 213-213	2.2	
287	Pan-HER tyrosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemo-naïve patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 483-483	2.2	
286	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 386-386	2.2	
285	Association of a combined panel of tumor infiltrating lymphocytes, plasma cells, and macrophages with recurrence of localized clear cell (cc) renal cell carcinoma (RCC) undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 502-502	2.2	
284	The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16026-e16026	2.2	
283	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5079-5079	2.2	
282	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3068-3068	2.2	
281	Multiplexed comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16014-e16014	2.2	
280	Circulating cell-free DNA profiling for potentially actionable targets in metastatic castration resistant prostate cancer (mCRPC) using next-generation sequencing on droplet volumes of plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16579-e16579	2.2	
279	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016 , 2, 341-349		4
278	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
277	Combination therapy for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2016 , 4, 100	3.2	16
276	Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 497-506	2.7	11
275	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1213-1224	7.3	73
274	Prostate Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 19-30	7.3	473
273	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 331-40	3.3	9

272	Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. <i>European Urology</i> , 2016 , 70, 203	10.2	1
271	Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. <i>Cell Cycle</i> , 2016 , 15, 819-26	4.7	27
270	Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2016 , 13, 306-7	5.5	15
269	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
268	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1113-1120	3.8	5
267	Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. <i>Lancet Oncology</i> , 2016 , 17, 1477-1478	21.7	2
266	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
265	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 2997-3004	4.4	9
264	Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 309-318	3.3	36
263	Corticosteroids in the management of prostate cancer: a critical review. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 6	5.4	20
262	Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 178-84	3.3	12
261	Editorial Comment. <i>Journal of Urology</i> , 2015 , 194, 329-30	2.5	
260	Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?. <i>Oncologist</i> , 2015 , 20, 461-3	5.7	4
259	Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 469-75	3.3	5
258	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 251-63	7	7
257	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. <i>European Urology</i> , 2015 , 68, 850-8	10.2	58
256	Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2015 , 115, 854-5	5.6	4
255	Danger on a half shell: <i>Vibrio vulnificus</i> septicemia. <i>American Journal of Medicine</i> , 2015 , 128, 475-6	2.4	4

254	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 136-45	7	25
253	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 228-37	7	77
252	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). <i>BJU International</i> , 2015 , 116, 17-29	5.6	14
251	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 3420-7	12.9	20
250	Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e217-e221	3.3	13
249	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 250-6	3.3	5
248	Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 171-7.e1	3.3	8
247	The expanding role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2637-2640	3.6	1
246	Emerging agents for the therapy of advanced prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2775-87	3.6	10
245	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
244	Future directions and targeted therapies in bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 361-76, x	3.1	21
243	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
242	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13
241	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. <i>PLoS ONE</i> , 2015 , 10, e0139267	3.7	28
240	Docetaxel for the treatment of bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1657-64.9	3.9	13
239	Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial. <i>European Urology</i> , 2015 , 68, 1098-9	10.2	
238	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 257-76	7	27
237	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 185-92	3.3	2

236	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4571-TPS4571	2.2	6
235	KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4572-TPS4572	2.2	9
234	A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4575-TPS4575	2.2	4
233	Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 305-305	2.2	3
232	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 311-311	2.2	1
231	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 426-426	2.2	7
230	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 335-335	2.2	
229	Multiplatform comprehensive kinase analysis of penile squamous cell carcinoma (PSCC) to identify drivers and potentially actionable therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 389-389	2.2	1
228	Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 186-186	2.2	
227	Kinase gene expression profiling of metastatic tumor tissue to prioritize therapeutic targets in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 476-476	2.2	
226	Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 475-475	2.2	
225	Impact of obesity in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 346-346	2.2	
224	Safety of cisplatin in patients with urothelial carcinoma (UC) and renal dysfunction.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 321-321	2.2	
223	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4527-4527	2.2	
222	Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5057-5057	2.2	
221	Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16095-e16095	2.2	
220	Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15633-e15633	2.2	
219	Sequencing of chemotherapy and androgen-axis inhibitors (AIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16030-e16030	2.2	

218	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15583-e15583	2.2	
217	Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5031-5031	2.2	
216	Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15527-e15527	2.2	
215	Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15526-e15526	2.2	
214	Perioperative chemotherapy for muscle-invasive urothelial carcinoma of the bladder 2015 , 142-156		
213	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 48.e1-8	2.8	9
212	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2014 , 32, 235-242	4.3	18
211	Precision medicine for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 5-15	2.8	14
210	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 305-15	5.9	18
209	The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. <i>World Journal of Urology</i> , 2014 , 32, 669-76	4	26
208	Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 433-9	3.3	23
207	The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , 2014 , 65, 3-6	10.2	100
206	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 317-24	3.3	53
205	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 253-61	7	12
204	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 30.e15-21	2.8	10
203	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 130-7	3.3	26
202	Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju124	9.7	1552
201	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 395-8	3.3	11

200	Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 36.e27-34	2.8	9
199	Prostate cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 686-718	7.3	261
198	Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial. <i>Future Oncology</i> , 2014 , 10, 1819-26	3.6	6
197	An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. <i>Cancer</i> , 2014 , 120, 976-82	6.4	69
196	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
195	Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2014 , 114, E25-E31	5.6	32
194	Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. <i>Oncology Research and Treatment</i> , 2014 , 37, 772-6	2.8	19
193	Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. <i>Anti-Cancer Drugs</i> , 2014 , 25, 878-86	2.4	12
192	Update in systemic therapy of urologic malignancies. <i>Postgraduate Medicine</i> , 2014 , 126, 44-54	3.7	6
191	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 501-8	2.8	25
190	Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 440-6	3.3	26
189	Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 71-3	3.3	34
188	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2014 , 40, 190-6	14.4	57
187	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , 2014 , 9, 195-204	5	16
186	The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4593-TPS4593	2.2	3
185	Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 223-223	2.2	1
184	Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 324-324	2.2	4
183	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 336-336	2.2	1

182	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 353-353	2.2	1
181	Distribution and geographic accessibility of prostate cancer clinical trials in the United States.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 59-59	2.2	1
180	External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4542-4542	2.2	
179	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15616-e15616	2.2	
178	Impact of African American (AA) race on outcomes with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15503-e15503	2.2	
177	Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy and androgen pathway inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5101-TPS5101	2.2	
176	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4514-4514	2.2	
175	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13547-e13547	2.2	
174	Immunohistochemistry (IHC) to enhance the prognostic allocation of locally advanced and metastatic urothelial cancer (UC) undergoing first-line chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4547-4547	2.2	
173	Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5047-5047	2.2	
172	A phase I study of BPX-201 vaccine plus AP1903 for chemo-naive metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3132-TPS3132	2.2	
171	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13502-e13502	2.2	
170	Identification of potentially targetable kinases by concurrent high-throughput functional kinomics and RNA-sequencing (seq) of muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4553-4553	2.2	
169	Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 341-341	2.2	
168	Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 28-28	2.2	
167	Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 43-43	2.2	
166	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 383-383	2.2	
165	Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 409-409	2.2	

164	The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. <i>Anticancer Research</i> , 2014 , 34, 3377-82	2.3	4
163	The preclinical activity of lenalidomide in indolent urothelial carcinoma. <i>Anticancer Research</i> , 2014 , 34, 3383-9	2.3	3
162	The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. <i>Prostate</i> , 2013 , 73, 267-77	4.2	41
161	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. <i>World Journal of Urology</i> , 2013 , 31, 1535-9	4	45
160	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. <i>World Journal of Urology</i> , 2013 , 31, 1211-7	4	11
159	Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. <i>World Journal of Urology</i> , 2013 , 31, 77-82	4	17
158	A new approach to second-line therapy for urothelial cancer?. <i>Lancet Oncology</i> , 2013 , 14, 682-4	21.7	5
157	Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 423-30	3.3	29
156	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
155	Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. <i>European Urology</i> , 2013 , 63, 371-8	10.2	39
154	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. <i>European Urology</i> , 2013 , 63, 58-66	10.2	133
153	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013 , 31, 5-11	4	27
152	The impact of gender on outcomes in patients with metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 346-52	3.3	13
151	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 495-500	3.3	16
150	Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1457-63	2.8	11
149	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 316-20	3.3	4
148	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 80-9	7	49
147	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. <i>European Urology</i> , 2013 , 63, 717-23	10.2	88

146	Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 175-81	3.3	74
145	Prognosis of renal-cell carcinoma: recognising host genetics. <i>Lancet Oncology, The</i> , 2013 , 14, 9-10	21.7	1
144	Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. <i>Cancer</i> , 2013 , 119, 1994-8	6.4	10
143	Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. <i>Current Urology Reports</i> , 2013 , 14, 174-83	2.9	13
142	Optimal management of metastatic renal cell carcinoma: current status. <i>Drugs</i> , 2013 , 73, 427-38	12.1	84
141	A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 234-40	2.8	1
140	Emerging drugs for urothelial carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 477-94	3.7	8
139	Current preclinical models for the advancement of translational bladder cancer research. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 121-30	6.1	23
138	Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. <i>Cancer</i> , 2013 , 119, 3020-6	6.4	6
137	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. <i>Cancer</i> , 2013 , 119, 3012-9	6.4	65
136	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
135	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. <i>BJU International</i> , 2013 , 111, 1215-21	5.6	43
134	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
133	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 256-256	2.2	5
132	Proportion of elderly patients with advanced bladder cancer receiving cisplatin-based chemotherapy: A large Medicare database study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 276-276	2.2	1
131	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 301-301	2.2	2
130	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 398-398	2.2	1
129	Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 79-79	2.2	2

128	Clinical Management of Elderly Patients with Metastatic Prostate Cancer Chemotherapy 2013 , 179-201		
127	Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 251-251	2.2	
126	Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 111-111	2.2	
125	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 353-353	2.2	1
124	The preclinical anti-angiogenic and pro-apoptotic activity of lenalidomide in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 294-294	2.2	
123	CEP-11981, a small molecule inhibitor of multiple angiogenic targets, in a preclinical system of urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 293-293	2.2	
122	Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 397-397	2.2	
121	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 347-347	2.2	
120	Cisplatin-associated nephrotoxicity in clinical trials using serum creatinine (SCr) versus calculated glomerular filtration rate (GFR) as inclusion criterion: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 272-272	2.2	
119	Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 269-269	2.2	
118	Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , 2012 , 61, 363-9	10.2	32
117	Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Eur Urol</i> 2012;61:363B. <i>European Urology</i> , 2012 , 61, 363-9	10.2	
116	Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. <i>European Urology</i> , 2012 , 61, 237-42	10.2	54
115	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 61, 639-47	10.2	24
114	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. <i>European Urology</i> , 2012 , 61, 307-16	10.2	43
113	Novel molecular targets for the therapy of castration-resistant prostate cancer. <i>European Urology</i> , 2012 , 61, 950-60	10.2	54
112	Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. <i>BJU International</i> , 2012 , 110, E461-8	5.6	28
111	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47

110	Clinical and pharmacokinetic evaluation of satraplatin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 103-11	5.5	27
109	Trends in the use of cytoreductive nephrectomy in the United States. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 159-63	3.3	19
108	Intracranial meningeal carcinomatosis in metastatic castration resistant prostate cancer: will extension of survival increase the incidence?. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 271-3	3.3	2
107	Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 239-45	3.3	17
106	A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 523-33	10.2	162
105	Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 607-13	2.8	89
104	Novel molecular targets for the therapy of urothelial carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 499-513	6.4	1
103	Immunotherapy for castration-resistant prostate cancer. <i>Urologic Clinics of North America</i> , 2012 , 39, 465-84	3.4	6
102	Abiraterone acetate for metastatic prostate cancer. <i>Lancet Oncology</i> , 2012 , 13, 958-9	21.7	1
101	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2012 , 38, 919-25	14.4	45
100	Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. <i>Journal of Urology</i> , 2012 , 188, 398-404	2.5	78
99	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. <i>Cancer</i> , 2012 , 118, 5947-54	6.4	31
98	The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. <i>Current Oncology Reports</i> , 2012 , 14, 295-306	6.3	24
97	Neoadjuvant chemotherapy for invasive bladder cancer. <i>Current Urology Reports</i> , 2012 , 13, 136-46	2.9	16
96	Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 6-14	3.3	22
95	Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 1-5	3.3	42
94	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4416-26	2.2	152
93	Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 163-6	2.7	8

92	Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1837-40	9.7	27
91	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 507-12	2.2	151
90	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28
89	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4524-4524	2.2	4
88	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4525-4525	2.2	1
87	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4623-4623	2.2	1
86	Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4644-4644	2.2	1
85	Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15003-e15003	2.2	1
84	Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4675-TPS4675	2.2	1
83	Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 282-282	2.2	3
82	Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 285-285	2.2	2
81	The preclinical activity of lenalidomide in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15002-e15002	2.2	
80	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4678-TPS4678	2.2	
79	Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21016-e21016	2.2	
78	Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 456-61	2.5	70
77	Recent advances in immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 997-1009	5.4	15
76	Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 682-9	2.8	41
75	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology, The</i> , 2011 , 12, 211-4	21.7	186

74	Contemporary management of metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2011 , 21, 241-7	2.8	7
73	The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2011 , 60, 270-8	10.2	39
72	The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. <i>Cancer</i> , 2011 , 117, 3963-71	6.4	30
71	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011 , 108, 687-92	5.6	19
70	Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. <i>Journal of Urology</i> , 2011 , 185, 1216-21	2.5	27
69	Diagnosis and management of urothelial carcinoma of the bladder. <i>Postgraduate Medicine</i> , 2011 , 123, 43-55	3.7	24
68	Hypomethylating agents for urologic cancers. <i>Future Oncology</i> , 2011 , 7, 447-63	3.6	5
67	Cabazitaxel for the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2011 , 7, 15-24	3.6	12
66	GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. <i>Clinical Cancer Research</i> , 2011 , 17, 7174-82	12.9	28
65	Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. <i>Urologia Internationalis</i> , 2011 , 87, 42-8	1.9	17
64	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2432-8	2.2	349
63	Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 949-57	3.5	8
62	Epigenetics in prostate cancer. <i>Prostate Cancer</i> , 2011 , 2011, 580318	1.9	46
61	Chemotherapy for castration-resistant prostate cancer 2011 , 80-90		
60	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. <i>International Journal of Urology</i> , 2010 , 17, 228-40	2.3	7
59	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. <i>OncoTargets and Therapy</i> , 2010 , 3, 147-55	4.4	12
58	Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2010 , 6, 665-79	3.6	20
57	First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?. <i>Journal of Clinical Oncology</i> , 2010 , 28, e441-2; author reply e443-4	2.2	18

56	Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, e205-7; author reply e208	2.2	8
55	Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 439-50	3.5	5
54	Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1128-35	6.1	24
53	Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. <i>Journal of Urology</i> , 2010 , 184, 888-94	2.5	52
52	pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2010 , 184, 470-4	2.5	25
51	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology</i> , 2010 , 11, 861-70	21.7	105
50	Neoadjuvant systemic therapy for urological malignancies. <i>BJU International</i> , 2010 , 106, 6-22	5.6	21
49	Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. <i>Investigational New Drugs</i> , 2010 , 28, 194-8	4.3	9
48	Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. <i>European Urology</i> , 2010 , 58, 112-7	10.2	37
47	A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. <i>Cancer</i> , 2010 , 116, 3595-602	6.4	19
46	Emerging vaccine therapy approaches for prostate cancer. <i>Reviews in Urology</i> , 2010 , 12, 25-34	1	11
45	Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1772-8	6.1	13
44	Novel agents for advanced bladder cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 37-50	5.4	
43	Satraplatin for the therapy of castration-resistant prostate cancer. <i>Future Oncology</i> , 2009 , 5, 931-40	3.6	7
42	Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. <i>Cancer</i> , 2009 , 115, 4104-9	6.4	133
41	Everolimus for renal cell carcinoma: predictive factors for response and future directions. <i>Medical Oncology</i> , 2009 , 26, 46-53	3.7	
40	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. <i>Update on Cancer Therapeutics</i> , 2009 , 3, 133-145		2
39	Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 391-9	2.8	66

38	Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. <i>Journal of Urology</i> , 2009 , 182, 459-65; discussion 465	2.5	14
37	Patient selection for phase II trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 216-9	2.7	5
36	Novel agents for muscle-invasive and advanced urothelial cancer. <i>BJU International</i> , 2008 , 101, 937-43	5.6	9
35	Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. <i>BJU International</i> , 2008 , 102, 1354-60	5.6	14
34	Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2008 , 6, 134-7	3.3	6
33	Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008 , 6 Suppl 1, S29-36	3.3	3
32	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 253-61	5.9	68
31	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1885-93	4	2
30	Trial design for metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3647-8; author reply 3648-9	2.2	1
29	Current optimal chemotherapy for advanced urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 51-61	3.5	5
28	Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. <i>Cancer</i> , 2008 , 112, 2519-2519	6.4	
27	Neoadjuvant therapy as a paradigm to develop systemic cancer therapy. <i>Drug Development Research</i> , 2008 , 69, 388-397	5.1	
26	Axitinib for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 741-8	5.9	46
25	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. <i>Cancer</i> , 2007 , 110, 2628-39	6.4	16
24	Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 457-9	3.3	9
23	Pazopanib: a novel multitargeted tyrosine kinase inhibitor. <i>Current Oncology Reports</i> , 2007 , 9, 115-9	6.3	155
22	Recent advances in the therapy of renal cancer. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 233-42	5.4	6
21	Lapatinib plus capecitabine in breast cancer. <i>New England Journal of Medicine</i> , 2007 , 356, 1471; author reply 1471-2	59.2	7

20	Management of recurrent testicular germ cell tumors. <i>Oncologist</i> , 2007 , 12, 51-61	5.7	25
19	Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. <i>Urology</i> , 2007 , 69, 1221-6	1.6	51
18	Vaccine therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 451-9	2.8	8
17	Neoadjuvant chemotherapy for bladder cancer. <i>Oncology</i> , 2007 , 21, 1673-81; discussion 1686-8, 1691, 1694	1.8	2
16	Systemic chemotherapy for urothelial cancer. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 34-42	3.3	1
15	Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. <i>Cancer</i> , 2006 , 106, 2610-6	6.4	160
14	Problems with the randomized discontinuation design. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4669-70; author reply 4670-1	2.2	4
13	Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. <i>Clinical Genitourinary Cancer</i> , 2006 , 5 Suppl 1, S31-9	3.3	4
12	Hormone refractory prostate cancer: Management and advances. <i>Cancer Treatment Reviews</i> , 2006 , 32, 90-100	14.4	24
11	New approaches in hormone refractory prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006 , 29, 196-201	2.7	11
10	Bladder cancer update. Current evaluation methods and standard of care. <i>Postgraduate Medicine</i> , 2006 , 119, 30-7	3.7	
9	Perioperative chemotherapy for bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 133-44		17
8	PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 1100-1	6.4	1
7	Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4459-60	2.2	8
6	Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4458-9	2.2	
5	Bevacizumab in renal-cell cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 1674	59.2	9
4	Communicating the value of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 948-9	2.2	7
3	What to do when you discover testicular cancer. Helping patients overcome fear and choose treatment. <i>Postgraduate Medicine</i> , 1999 , 105, 229-36	3.7	4

2 Multi-targeted agents in the treatment of urothelial carcinoma353-361

1 ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition

1